[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UA99634C2 - Производные 1,2,4,-триазин-3,5-диона для лечения нарушений, реагирующих на модулирование рецептора допамина d3 - Google Patents

Производные 1,2,4,-триазин-3,5-диона для лечения нарушений, реагирующих на модулирование рецептора допамина d3

Info

Publication number
UA99634C2
UA99634C2 UAA201006793A UAA201006793A UA99634C2 UA 99634 C2 UA99634 C2 UA 99634C2 UA A201006793 A UAA201006793 A UA A201006793A UA A201006793 A UAA201006793 A UA A201006793A UA 99634 C2 UA99634 C2 UA 99634C2
Authority
UA
Ukraine
Prior art keywords
c3alkyl
fluorinated
dopamine
formula
respond
Prior art date
Application number
UAA201006793A
Other languages
English (en)
Ukrainian (uk)
Inventor
Вільфрід Брайє
Шон Кольм ТЕРНЕР
Андреас ХАУПТ
Удо ЛАНГЕ
Ерве Женест
Карла ДРЕШЕР
Ліліане УНГЕР
Анна Люсія Йонген-Рело
Антон Бєспалов
Original Assignee
Ебботт Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA99634(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ебботт Гмбх Унд Ко. Кг filed Critical Ебботт Гмбх Унд Ко. Кг
Publication of UA99634C2 publication Critical patent/UA99634C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение раскрывает соединения формулы (I) EMBED ISISServer , (I) в которой А представляет собой насыщенную или ненасыщенную углеводную цепь с длиной цепи от 4 до 6 атомов углерода, причем углеводная цепь не замещена или замещена 1, 2 или 3 метильными группами; R1 выбран из группы, состоящей из водорода, С1-С3алкила и фторированного С1-С3-алкила; R2 представляет собой водород, галоген, цианогруппу, С1-С3алкил, С1-С3алкоксигруппу, фторированный С1-С3алкил или фторированную С1-С3алкоксигруппу; R3 вибран из группы, що состоящей из разветвленного С4-С6-алкила и С3-С6циклоалкила, и R4 представляет собой С1-С6алкил, С3-С6циклоалкил, фторированный С1-С3алкил и фторированный С3-С6циклоалкил, физиологически приемлемые соли указанных соединений и их N-оксиды; фармацевтические композиции, на основе этих соединений, и способ лечения заболеваний, положительно реагирующих на антагонисты рецептора допамина D3 или агонисты допамина D3.
UAA201006793A 2007-11-02 2008-10-31 Производные 1,2,4,-триазин-3,5-диона для лечения нарушений, реагирующих на модулирование рецептора допамина d3 UA99634C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07119927 2007-11-02

Publications (1)

Publication Number Publication Date
UA99634C2 true UA99634C2 (ru) 2012-09-10

Family

ID=40210491

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201006793A UA99634C2 (ru) 2007-11-02 2008-10-31 Производные 1,2,4,-триазин-3,5-диона для лечения нарушений, реагирующих на модулирование рецептора допамина d3

Country Status (29)

Country Link
US (1) US8492540B2 (ru)
EP (1) EP2217593B1 (ru)
JP (1) JP5559694B2 (ru)
KR (1) KR20100094491A (ru)
CN (1) CN101932574B (ru)
AR (1) AR069150A1 (ru)
AT (1) ATE556069T1 (ru)
AU (1) AU2008320814B2 (ru)
BR (1) BRPI0818726A2 (ru)
CA (1) CA2704533C (ru)
CL (1) CL2008003253A1 (ru)
CO (1) CO6280473A2 (ru)
CR (1) CR11410A (ru)
DO (1) DOP2010000126A (ru)
EC (1) ECSP10010227A (ru)
ES (1) ES2386691T3 (ru)
HK (1) HK1146628A1 (ru)
IL (1) IL205468A0 (ru)
MX (1) MX2010004830A (ru)
MY (1) MY154066A (ru)
NZ (1) NZ585051A (ru)
PA (1) PA8802101A1 (ru)
PE (1) PE20090950A1 (ru)
RU (1) RU2478633C2 (ru)
TW (1) TWI463984B (ru)
UA (1) UA99634C2 (ru)
UY (1) UY31448A1 (ru)
WO (1) WO2009056625A1 (ru)
ZA (1) ZA201003593B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9505753B2 (en) 2012-08-08 2016-11-29 The Johns Hopkins University Inhibitors of D-amino acid oxidase
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
UY35420A (es) 2013-03-15 2014-10-31 Abbvie Inc Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
AR095264A1 (es) 2013-03-15 2015-09-30 Abbvie Deutschland Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
KR102643833B1 (ko) 2022-06-30 2024-03-06 현대제철 주식회사 이강종 연연주시 강종 예측 정합성 증대 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4425144A1 (de) 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
DE4425143A1 (de) 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
FR2727682A1 (fr) 1994-12-02 1996-06-07 Pf Medicament Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
DE19728996A1 (de) 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
FR2769913B1 (fr) * 1997-10-16 2000-03-10 Pf Medicament Nouveaux derives cyclohexaniques difonctionnalises en 1, 4, leur preparation et leur application therapeutique humaine
DE10311065A1 (de) 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
TW200510395A (en) * 2003-06-05 2005-03-16 Abbott Gmbh & Co Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
DE102004027359A1 (de) * 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyridin-2-onverbindungen und deren Verwendung
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
DE602005018366D1 (de) * 2004-08-09 2010-01-28 Abbott Gmbh & Co Kg Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen
AU2005311452A1 (en) * 2004-12-02 2006-06-08 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulaiont of the dopamine D3 receptor
DE102004061593A1 (de) * 2004-12-21 2006-06-22 Abbott Gmbh & Co. Kg Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung
CA2692268A1 (en) * 2007-06-28 2009-01-08 Intervet International B.V. Substituted piperazines as cb1 antagonists

Also Published As

Publication number Publication date
DOP2010000126A (es) 2010-06-15
IL205468A0 (en) 2010-12-30
ATE556069T1 (de) 2012-05-15
CL2008003253A1 (es) 2009-11-13
TW200927132A (en) 2009-07-01
CA2704533C (en) 2016-09-06
CN101932574B (zh) 2014-07-23
AU2008320814A1 (en) 2009-05-07
MY154066A (en) 2015-04-30
ZA201003593B (en) 2011-02-23
TWI463984B (zh) 2014-12-11
RU2478633C2 (ru) 2013-04-10
EP2217593A1 (en) 2010-08-18
AU2008320814B2 (en) 2013-07-11
CA2704533A1 (en) 2009-05-07
NZ585051A (en) 2012-03-30
PA8802101A1 (es) 2009-08-26
CR11410A (es) 2010-09-13
WO2009056625A1 (en) 2009-05-07
ECSP10010227A (es) 2010-08-31
CN101932574A (zh) 2010-12-29
US20100311755A1 (en) 2010-12-09
ES2386691T3 (es) 2012-08-27
MX2010004830A (es) 2010-10-20
US8492540B2 (en) 2013-07-23
RU2010122337A (ru) 2011-12-10
UY31448A1 (es) 2009-05-29
CO6280473A2 (es) 2011-05-20
KR20100094491A (ko) 2010-08-26
JP5559694B2 (ja) 2014-07-23
PE20090950A1 (es) 2009-08-08
HK1146628A1 (en) 2011-06-24
AR069150A1 (es) 2009-12-30
EP2217593B1 (en) 2012-05-02
BRPI0818726A2 (pt) 2015-04-22
JP2011502971A (ja) 2011-01-27

Similar Documents

Publication Publication Date Title
PH12013500848A1 (en) Trpv1 antagonists and uses thereof
UA101601C2 (ru) Ингибиторы амидогидролазы жирных кислот
WO2008076243A3 (en) Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
EP1921919A4 (en) IMPROVED LIPOLYTIC PREPARATION WITH PROLONGED RELEASE FOR TREATMENT OF LOCALIZED ADIPOSE TISSUE
WO2006119507A3 (en) Non-nucleotide composition and method for inhibiting platelet aggregation
UA99361C2 (ru) ТРИАЗИНЫ КАК ИНГИБИТОРЫ PI3-КИНАЗЫ I mtor
MX2007012936A (es) Derivados de dihidrobenzofurano y usos de los mismos.
WO2007129195A3 (en) 4-pyrimidine-5-amino-pyrazole compounds
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
BRPI0910182A2 (pt) composto de fórmula (i), composição farmacêutica, método de tratamento de um distúrbio e uso de um composto"
UA96777C2 (ru) Фенилпропионамидные соединения и их применение как опиоидных агонистов
UA99634C2 (ru) Производные 1,2,4,-триазин-3,5-диона для лечения нарушений, реагирующих на модулирование рецептора допамина d3
EA201170795A1 (ru) Антагонисты ccr2 группы 4-азетидинил-1-гетероарил-циклогексанола
WO2009061374A3 (en) Deuterated fingolimod
DE602004027409D1 (de) Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
EA200901391A1 (ru) Пиримидинилпиперазины, применимые в качестве лигандов рецепторов d/d
WO2010100133A3 (fr) Derives indoliques pour le traitement de maladies neurodegeneratives
BRPI0515261A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo
MX2009012518A (es) Derivados de piperidina 4,4-disubstituidos.
MX2010004300A (es) Ligandos de (1,4-diaza-biciclo [3,2,2]non-6-en-4-il)-heterociclil- metanona para receptores nicotinicos de acetilcolina, utiles para el tratamiento de enfermedad.
WO2008059130A9 (fr) Thionucléosides et applications pharmaceutiques
EA201070603A1 (ru) Лекарственное средство, активное в отношении невропатической боли
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
TW200510395A (en) Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
TW200633710A (en) Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor